1. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. (June 2017) Authors: Iwakiri, Katsuhiko; Sakurai, Yuuichi; Shiino, Madoka; Okamoto, Hiroyuki; Kudou, Kentaro; Nishimura, Akira; Hiramatsu, Naoki; Umegaki, Eiji; Ashida, Kiyoshi Journal: Therapeutic advances in gastroenterology Issue: Volume 10:Number 6(2017) Page Start: 439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438). Issue 7 (July 2016) Authors: Otake, Kazuyoshi; Sakurai, Yuuichi; Nishida, Haruyuki; Fukui, Hideo; Tagawa, Yoshihiko; Yamasaki, Hitomi; Karashima, Masatoshi; Otsuka, Keiichi; Inatomi, Nobuhiro Journal: Advances in therapy Issue: Volume 33:Issue 7(2016) Page Start: 1140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study. Issue 11 (2nd November 2019) Authors: Kinoshita, Yoshikazu; Sakurai, Yuuichi; Takabayashi, Nobuyoshi; Kudou, Kentaro; Araki, Takahiro; Miyagi, Takuya; Iwakiri, Katsuhiko; Ashida, Kiyoshi Journal: Clinical and translational gastroenterology Issue: Volume 10:Issue 11(2019) Page Start: e00101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study. Issue 9 (September 2016) Authors: Sakurai, Yuuichi; Shiino, Madoka; Okamoto, Hiroyuki; Nishimura, Akira; Nakamura, Koki; Hasegawa, Setsuo Journal: Advances in therapy Issue: Volume 33:Issue 9(2016) Page Start: 1519 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Reply to the letter by Dr Graham concerning ethical and interpretation issues with vonoprazan-containing H. pylori eradication therapy. Issue 2 (3rd May 2016) Authors: Murakami, Kazunari; Sakurai, Yuuichi; Shiino, Madoka; Funao, Nobuo; Nishimura, Akira; Asaka, Masahiro Journal: Gut Issue: Volume 66:Issue 2(2017) Page Start: 386 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK‐438 (Vonoprazan) Doses in Healthy Male Japanese/non‐Japanese Subjects. Issue 6 (June 2015) Authors: Sakurai, Yuuichi; Nishimura, Akira; Kennedy, Gale; Hibberd, Mark; Jenkins, Richard; Okamoto, Hiroyuki; Yoneyama, Tomoki; Jenkins, Helen; Ashida, Kiyoshi; Irie, Shin; Täubel, Jörg Journal: Clinical and translational gastroenterology Issue: Volume 6:Issue 6(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Issue 9 (2nd March 2016) Authors: Murakami, Kazunari; Sakurai, Yuuichi; Shiino, Madoka; Funao, Nobuo; Nishimura, Akira; Asaka, Masahiro Journal: Gut Issue: Volume 65:Issue 9(2016) Page Start: 1439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗